Document is current
Any future updates will be listed below
-
Authors
Haue, Amalie D.
Armenteros, Jose J. Almagro
Holm, Peter C.
Eriksson, Robert
Moseley, Pope L.
Køber, Lars V.
Bundgaard, Henning
Brunak, Søren
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF17OC0027594)
Innovationsfonden (5184-00102B)
- License Information
-
More Information
Article History
Received: 4 March 2022
Accepted: 18 May 2022
First Online: 31 May 2022
Declarations
:
: The study was approved by the Danish Data Protection Agency (ref: 2015-54-0939 and SUND-2017-57) and Danish Health Authority (ref: FSEID-00001627 and FSEID-00003092).
: Not applicable. The paper contains summary level statistics only.
: Dr. Køber reports speaker’s honorarium from AstraZeneca, Novo Nordisk A/S, Novartis, and Boeheringer. Dr. Brunak reports ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK A/S and managing board memberships in Proscion A/S and Intomics A/S.
